Table 13.
Longitudinal changes in AGR, the revised ocular inflammatory activity score, and logMAR BCVA according to treatment response
| Variable | Group | Baseline | 14 d | 6 weeks | 3 months | P for time effect | P for group effect | P for interaction |
|---|---|---|---|---|---|---|---|---|
| AGR | Good treatment response n = 148 | 1.36 ± 0.25 | 1.42 ± 0.24 | 1.48 ± 0.23 | 1.54 ± 0.22 | < 0.001 | < 0.001 | 0.002 |
| AGR | Poor treatment response n = 52 | 1.15 ± 0.22 | 1.18 ± 0.21 | 1.21 ± 0.23 | 1.24 ± 0.24 | < 0.001 | < 0.001 | 0.002 |
| Revised ocular inflammatory activity score, 0–12 | Good treatment response n = 148 | 5.05 ± 1.38 | 3.24 ± 1.80 | 1.97 ± 1.35 | 1.08 ± 0.95 | < 0.001 | < 0.001 | 0.188 |
| Revised ocular inflammatory activity score, 0–12 | Poor treatment response n = 52 | 7.04 ± 1.15 | 5.44 ± 2.14 | 4.48 ± 2.07 | 3.75 ± 1.78 | < 0.001 | < 0.001 | 0.188 |
| logMAR BCVA | Good treatment response n = 148 | 0.46 ± 0.25 | 0.38 ± 0.22 | 0.29 ± 0.19 | 0.21 ± 0.16 | < 0.001 | < 0.001 | 0.004 |
| logMAR BCVA | Poor treatment response n = 52 | 0.76 ± 0.34 | 0.70 ± 0.31 | 0.64 ± 0.30 | 0.58 ± 0.28 | < 0.001 | < 0.001 | 0.004 |
Note: Data are presented as mean±standard deviation. The revised ocular inflammatory activity score was calculated as the sum of the anterior chamber cell score, vitreous haze score, OCT activity score, and FFA leakage score, yielding a total score of 0–12. At baseline and 3 months, the revised score was calculated directly from the four component scores. Because the component-level scores were not separately retained at 14 days and 6 weeks in the current working dataset, the values at these two time points were reconstructed by removing the contemporaneous visual impairment component from the original five-domain score and constraining the resulting score to the prespecified range of 0–12. Longitudinal changes were assessed using linear mixed-effects models including treatment-response group, follow-up time, and their interaction as fixed effects, with a patient-specific random intercept. AGR, albumin-to-globulin ratio; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; OCT, optical coherence tomography; FFA, fundus fluorescein angiography